Multicenter, randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU. Lung infection is a serious complication that may occur during hospital stay and may need artificial respiration or even develop during artificial ventilation for other causes. Current specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like loosening of secretions, eradicating bacteria or reducing inflammation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Median SOFA score increase >2 points on day 4
Timeframe: inclusion to day 4 after randomization
Median respiratory support-free days increase at day 28
Timeframe: Inclusion to day 28 after randomization
Percentage of subjects surviving/dying day 28
Timeframe: Inclusion to day 28 after randomization